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Background: While botulinum toxin A (BoNT-A) has become a more commonly used second-line treatment for
patients with detrusor overactivity, it remains unknown whether the impacts of this therapy may persist to influence
other therapies such as sacral neuromodulation. In this preclinical study we have evaluated urodynamic functions
to intradetrusor injection of BoNT-A and the bladder inhibitory effects of spinal nerve stimulation (SNS) following
BoNT-A treatment.
Methods: Female rats were anesthetized with 3 % isoflurane. BoNT-A (2 units, 0.2 ml) or saline were injected into
the detrusor. Rats then were housed for 2 days to 1 month before neuromodulation study. Monopolar electrodes
were placed under each of the L6 spinal nerve bilaterally under urethane anesthesia. A bladder cannula was
inserted via the urethra for saline infusion and intravesical pressure recording.
Results: Intradetrusor injection of BoNT-A for 1–2 weeks or 1 month significantly increased bladder capacity
compared with saline injection (p < 0.05, two-way ANOVA). Following BoNT-A, SNS attenuated the frequency
of bladder contractions, either eliminating bladder contractions or reducing the contraction frequency during
electrical stimulation. Inhibition of the contraction frequency by SNS following BoNT-A treated rats was not
different from that measured following saline injection.
Conclusions: BoNT-A increased the bladder capacity, but compensating for additional saline infusion to the
enlarged urinary bladder in BoNT-A pretreated rats, the bladder contractions induced by bladder filling were attenuated
by SNS. BoNT-A did not alter the ability of SNS to inhibit bladder contraction following intradetrusor injection
of BoNT-A for 2 days, 1–2 weeks or 1 month. These results support further pre-clinical and clinical studies to
evaluate potential interactions or combination therapy with neuromodulation and intradetrusor BoNT-A
therapeutic approaches.
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Detrusor overactivity is a common medical problem
resulting in increased voiding frequency, urinary urgency
and urge incontinence. Anti-muscarinic drugs are gener-
ally used as first line therapies while mirabegron is a
first-in-class β3-adrenoceptor agonist licensed and has
shown to be effective and have a good safety profile [1].
If medications cannot be tolerated or do not provide* Correspondence: xin.su@medtronic.com
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creativecommons.org/publicdomain/zero/1.0/sufficient symptomatic relief, the most common second
line treatment options are 1) sacral neuromodulation
(InterStim® Therapy) via stimulation of the spinal nerve
(S3), which is efficacious in 70-80 % population of
patients with urge incontinence and increased frequency
[2]; and 2) intradetrusor injection of botulinum toxin
type A (BoNT-A) which improves detrusor overactivity
and increases bladder capacity [3, 4].
Urodynamic studies have shown BoNT-A injection to
increase maximum cystometric capacity and bladder
compliance [5–10]. With the increasing use of BoNT-A,
many patients may receive both of these second linedistributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
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who are dissatisfied with or fail BoNT-A treatment with
a mean interval of 23 months between the BoNT-A and
the sacral neuromodulation test stimulation, respond
successfully to InterStim Therapy [11]. Systematic stud-
ies of potential interactions of sacral neuromodulation
and BoNT-A have not been performed. One unknown
question relates to the potential impact of prior BoNT-A
treatment upon subsequent neuromodulation. Specific-
ally, does prior treatment with BoNT-A alter patient
success rates to neuromodulation therapy? No clinical or
preclinical data is available to address this question from
either efficacy or safety perspectives.
We have utilized the rat model of the bladder mictur-
ition reflex contraction (BRC) to screen for potential
interactions between BoNT-A and neuromodulation
[12–14]. Spinal nerve stimulation (SNS) results in an
inhibition of the frequency of BRC. Stimulation parame-
ters (e.g. stimulation frequency and current intensity)
have been optimized systemically. Our previous work in
the rat [15, 16] demonstrates a positive intensity-
dependent bladder inhibitory effect in response to elec-
trical stimulation of the L6 spinal nerve. In the present
study, we characterized the relationship between current
intensity of SNS and bladder contraction frequency in
rats pretreated with intradetrusor injection of either
saline or BoNT-A.
Methods
Animals and study design
A total of 79 female Sprague–Dawley rats, 200–300 g
were used, 44 in the BoNT-A treatment group (intrade-
trusor injection) and 35 in the saline treatment group.
After 2 days to 1 month of the treatment, all rats were
anesthetized with urethane and examined urodynami-
cally to determine the bladder compliance or bladder
micturition reflex following the treatment. The inhibi-
tory effects of SNS on BRC were also studied. During
the urodynamic study, rats were maintained at 37 °C
with a heating pad (Viking Medical, Medford Lakes, NJ)
and were euthanized by CO2 asphyxia upon completion
of experimental procedures. The experimental protocols
were approved by the Medtronic Institutional Animal
Care and Use Committee as well as the Non-clinical
Research Board (Minneapolis, MN).
Intradetrusor injection
Rats were anesthetized with 3 % isoflurane. The urinary
bladder was exposed via a small suprapubic incision
under sterile conditions. Two units (0.2 ml) of BoNT-A
(BOTOX®, manufactured by Allergan, Besse Medical,
West Chester, OH) or saline were injected into the
whole detrusor randomly and evenly (10–16 μl per site)
through a 30-gauge needle. The same volume of normalsaline was injected into the detrusor at the same posi-
tions as a control group. The rectus fascia was closed
with an absorbable suture, and the skin was closed with
silk sutures. Animals then were housed for 2 days (9 in
saline and 10 in BoNT-A), 1 week (11 in saline and 15
in BoNT-A) or 2 weeks (4 in saline and 6 in BoNT-A,
grouped together with 1 week treatment), or 1 month
(11 in saline and 13 in BoNT-A) before the urodynamic
studies.
Neuromodulation of L6 SNS
Rats were anesthetized with urethane (two i.p. injections,
4 min apart, total 1.2 g/kg, 200 mg/ml in saline, Sigma-
Aldrich, St. Louis, MO). To deliver electrical stimulation,
the skin around the dorsal sacral and thoracic area was
shaved and a dorsal midline incision was made from
approximately L3 to S2, the L6/S1 posterior processes
were exposed. The S1 processes were removed and the
L6 nerve trunks were localized caudal and medial to the
sacroiliac junction. Electrodes were made from teflon-
coated, 40-gauge, stainless steel wire with the coating
removed from a 0.5 cm section (Cooner Wire Co.,
Chatsworth, CA) and was placed under each of the L6
spinal nerve bilaterally. After the wire electrode(s) were
positioned, silicone adhesive (Kwik-Cast, World Preci-
sion Instruments, Inc, Fl, USA) was applied to cover the
wire around the nerve, and the skin incision was sutured
shut. The electrode(s) were connected to a Grass S88
stimulator (Grass Medical Instruments), through stimulus
isolation unit(s) (SIU-BI, Grass Medical Instruments). A
needle electrode under the skin of the tail served as the
ground.
To record bladder contractions, a polyethylene
cannula (PE50) was inserted into the bladder via the
urethra, and secured with a suture tie. The urethral
cannula was connected via a T- connector to a pressure
transducer (MLT0380D, ADInstruments, Colorado
Springs, CO, USA) and data acquisition system (ML880/P,
ADInstruments). The intravesical pressure signal was
amplified for recording (ML228, ADInstruments). The
other end of the T-connector was attached to a syringe
pump.
Urodynamic studies
To induce BRC, saline was infused into the bladder via
the syringe pump at a rate of 50 μl per minute to induce
a micturition reflex (here defined as a bladder contrac-
tion of a magnitude >10 mmHg). The infusion rate was
then lowered to 10 μl per minute and continued until
3–5 consecutive contractions were established. At this
time, the saline infusion was terminated, and the BRC
continued.
Electrical stimulation of the spinal nerve evoked hind-
toe twitches and/or pelvic floor muscle contraction. In
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as the lowest current required to evoke the first, barely
observable, muscle contraction. Biphasic pulses (pulse
width 0.1 ms) of different intensities (0.8 x Tmot, Tmot
and 2 x Tmot) were applied at a frequency of 10 Hz to
stimulate the spinal nerve.
After a 15 min control period, nerve stimulation was
applied; the BRC were recorded for additional 20 min
post stimulation. Initially, single current intensity stimu-
lation was applied for a total of 10 min (20 in saline and
25 in BoNT-A) in one rat. In some other experiments
(15 in saline and 19 in BoNT-A), all intensities in the
order 0.8 x Tmot, Tmot and 2 x Tmot for a total of
15 min were tested in the same rat. Since there is no
difference in sensitivity to nerve stimulation between
two stimulation modalities [14–16], the data were
grouped according the test intensity.
Data analysis
To evaluate the bladder compliance/capacity, a few
cystometry parameters were assessed once the first mic-
turition reflex was established including basal bladder
pressure (BP, mmHg), threshold pressure (TP, mmHg,
pressure before the micturition occurred), and bladder
capacity (ml, volume infused to induce a micturition
reflex, interval x 0.05 μl•min-1). The bladder compliance
was assessed mathematically using the capacity divided
by the difference of BP with TP. Once the stable BRC is
established, two parameters of BRC were evaluated:
frequency/interval and amplitude between the maximum
pressure reached during voiding and after voiding in
mmHg in 5 min bins. When the BRC was completely
suppressed by high intensity stimulation, the frequency
of the bladder contraction was designated “0” and ampli-
tude data for that interval was excluded. All data were
compared to the mean response during the last 5 min
prior to stimulation.
All data are expressed as mean ± SEM. Results were
analyzed with two-way ANOVA with Bonferroni post-
hoc test by Prism 5 (GraphPad Software, Inc., San Diego,
CA). A value of p < 0.05 was considered statistically
significant.
Results
Following treatment of BoNT-A or saline, infusion of
saline into the bladder at a constant rate induced an
increase in bladder pressure. Until the TP for urin-
ation is reached, only a small increase in pressure
was observed. Figure 1a and b shows the two traces
of intravesical pressure from rats 1 month post intra-
detrusor injection of either saline or BoNT-A. More
saline infusion was required to evoke the bladder
micturition reflex in the rat pretreated with BoNT-A. Sum-
marized data in Fig. 1c demonstrate that intradetrusorinjection of BoNT-A for 1–2 weeks or 1 month signifi-
cantly increased bladder capacity (p = 0.008, two-way
ANOVA). We found no differences on compliance, TP and
BP between the control and BoNT-A groups (Fig. 1d, e and
f). Continuing the saline infusion (see Methods) resulted in
BRC. Once the BRC was established with large volume
infusion in BoNT-A treated rats, the baseline values of
contraction amplitude and contraction frequency from
BoNT-A treated rats were not different from that from
saline treated rats (Fig. 1g and h).
Without stimulation the BRC was similar following
saline or BoNT-A pretreatment (Fig. 2a and c). When
electrical stimulation of the spinal nerve was delivered it
attenuated the frequency of bladder contractions, either
eliminating bladder contractions completely or reducing
the contraction frequency during electrical stimulation
in both BoNT-A and saline treatments (Fig. 2b and d).
The contraction frequency returned to the prestimula-
tion value after termination of electrical stimulus.
Figure 3 summarizes the mean responses of BRC
responses during different intensities of SNS in saline or
BoNT-A treated rats. Two-way ANOVA analysis dem-
onstrates that BRC frequency was significantly decreased
by SNS at all current intensities tested following either
BoNT-A or saline injections (p < 0.05, vs time control
when stimulation was not applied).
Two days, 1–2 weeks and 1 month post BoNT-A injec-
tion, SNS at Tmot,10 Hz decreased the frequency of con-
tractions to 70.18 ± 25 % (n = 8), 52.14 ± 12 % (n = 16, p <
0.05), and 51.94 ± 12 % of controls (n = 12, p < 0.05, vs.
98.77 ± 5 % control without stimulation), respectively.
Using the same stimulation parameters, SNS de-
creased the frequency of contractions in saline pre-
treated rats, to 50.32 ± 12 % (n = 8, p < 0.05), 55.93 ±
15 % (n = 11, p < 0.05), and 45.45 ± 10 % of controls
(n = 9, p < 0.05, vs. 114.16 ± 8 % control without
stimulation), respectively. Inhibition of the contraction
frequency in BoNT-A treated rats was not different
from that measured in saline treated rats (p > 0.05).
SNS elicited relatively weak and inconsistent inhibition
on the amplitude of the bladder contractions (p < 0.05,
vs time control when stimulation was not applied, two-
way ANOVA). Figure 3b, d and f summarize effects of
SNS on amplitude of BRC.
Discussion
We have previously reported that SNS inhibits the
frequency of volume induced BRC, and that 10 Hz is the
optimally efficacious stimulation frequency in this model
system [15]. The inhibitory effects of SNS on bladder
contractions have also been shown to be intensity-
dependent, and the magnitude of the inhibition increases
with the applied current (stimulus intensity, 16). In the
present study, we used 10 Hz stimulation frequency and
Fig. 1 Urodynamic function in rats pretreated with saline or botolinium toxin A (BoNT-A). a and b. Raw traces of intravesical pressure recording
to intravesical saline infusion, 1 month following with saline or BoNT-A injections. c-f. Summary of cystemetry parameters before the first micturition
contraction occurred following saline infusion in rats with intradetrusor injection of saline and BoNT-A. g-h. Basal amplitude or frequency of bladder
contractions once bladder micturition reflex contraction was established in saline or BoNT-A pretreated rats. *p < 0.05, Two-way ANOVA, Bonferroni
post test. The number of animals is indicated in each symbol
Su et al. BMC Urology  (2015) 15:50 Page 4 of 7studied the intensity-response function of the bladder
micturition reflex to SNS in BoNT-A or saline treated
rats to establish the sensitivity of neuromodulation in
bladder control. Our data do not show a difference in
the magnitude of the inhibitory effect of neuromodula-
tion between BoNT-A and saline treated rats.
Intradetrusor injection of the BoNT-A dose used in
our study (2 units) was shown in a prior study to not
cause urinary retention in the rat [8]. Consistent with
these results, we did not observe any reduction in the
amplitude of bladder contraction following BoNT-A
treatment. The interval between BoNT-A injection and
urodynamic evaluation ranged from 2 days to 1 month.
BoNT-A significantly increased bladder capacity, 1–2weeks and 1 month following injection. This is consist-
ent with the time-course for the onset and duration of
the effect of BoNT-A by others. Significant inhibitory
effects on neurotransmitter release and urodynamic
function were observed 5–30 days after injection [7, 17].
Clinically, patients experience relief of sudden urges to
urinate, and a reduction in urine leakage starting several
days to 2 weeks following BoNT-A injection. In pa-
tients the effect has been show to persist for 3 to
9 months [18].
In our tests the effectiveness of BoNT-A alone was
demonstrated by its action on increasing bladder cap-
acity. This is consistent with studies reported by others
regarding effects of BoNT-A alone in the rat with
Fig. 2 Typical experimental records showing the bladder micturition reflex contraction (mmHg) 1 month following either BoNT-A (a and b) or
saline (c and d) intradetrusor injection without stimulation (a and c) or to L6 spinal nerve stimulation at motor threshold (Tmot) intensity (10 Hz,
pulse width 0.1 ms) for 10 min (b and d). Horizontal bars indicate duration of spinal nerve stimulation
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rats, BoNT-A attenuated non-voiding contractions [9].
In addition, BoNT-A has been also reported to suppress
acetic acid induced bladder hyperactivity and inflamma-
tory reactions [6, 8]. We did not examine the immuno-
histochemistry and histology changes on the detrusor
following BoNT-A injection in the present study. Others
have reported that the mechanism of BoNT-A on blad-
der control may be related to its inhibition on neuro-
transmitter release [17, 19–22]. This is reflected by an
increase in bladder capacity. Clinically BoNT-A results in
an increase in cystometric capacity. In studies reported
increases of 60 % ([23], spinal cord injured patients with
detrusor overactivity), 35-80 % ([24], pediatric neurogenic
bladder), and 100-200 % ([25], neurogenic detrusor over-
activity patients) have been observed.
Intradetrusor injection of BoNT-A increases bladder
capacity. Additional saline infusion was able to compen-
sate the enlarged urinary bladder in BoNT-A pretreated
rats and establish the BRC. Although the bladder cap-
acity is increased, the frequency of bladder contraction
in our model is not decreased, and the ability ofneuromodulation to inhibit BRC is unaffected. In the
present study, SNS produced an equal degree of bladder
inhibition following either saline or BoNT-A treatment.
The magnitude of inhibition was comparable to that
reported previously in this model [15, 16]. Therefore, in
BoNT-A treated rats, SNS produced a bladder inhibition
that occurred independent of the increased bladder cap-
acity produced by BoNT-A. It is likely that BoNT-A acts
via interference with the release of neurotransmitters
from peripheral nerve terminals and the response of
afferent activated dorsal horn neurons [26, 27] while
neuromodulation produced an inhibition of the BRC via
an action at a higher level CNS on the neuronal control
of the bladder reflex (e.g. the pontine micturition center
and cerebral cortex, [28]). If BoNT-A and SNS have
different sites of action, it would be logical that these ther-
apies may have independent effects on bladder inhibition.
The present results are not definitive. Detrusor over-
activity is often a multi-etiological disease. Our data
were obtained in normal and anesthetized rats. Only
BRC, not cystometric capacity was measured. However,
inhibition of the BRC is a consequence of an increased
Fig. 3 Effects of spinal nerve stimulation on the frequency (a, c and e) and amplitude (b, d and f) of the bladder micturition reflex contraction at
intensities relative to the motor threshold (Tmot) intensity (10 Hz, pulse width 0.1 ms). Responses are represented as a percentage of control
(%control), where the baseline response before stimulation is defined as 100 %. * p < 0.05, Two-way ANOVA, Bonferroni post test. The number of
animals is indicated in each symbol
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A does not appear to attenuate the bladder inhibitory
effects of neuromodulation, it is reasonable that an
equally increased bladder capacity would be observed
in rats pretreated with intradetrusor injection of
either BoNT-A or saline. In support, from a clinical
observation patients who are dissatisfied with or fail
BoNT-A treatment respond successfully to InterStim
Therapy [11]. The neuromodulation was evaluated
following a single injection of BoNT-A in this work.
Our findings encourage further pre-clinical studies
evaluating the combination of neuromodulation and
repeated intradetrusor injections of BoNT-A on uro-
dynamics in animals with normal and irritated blad-
der as well as controlled clinical evaluations of
therapy interactions or combinations using sacralneuromodulation with BoNT-A in patients with
detrusor overactivity.
Conclusions
Our study confirmed previous observations that intra-
detrusor injection of BoNT-A increases bladder cap-
acity in the rat. This increased capacity in BoNT-A
treated rats does not influence the frequency of the
BRC. Regardless of the interval between injection and
stimulation, treatment with BoNT-A does not appear
to influence the ability of SNS to inhibit BRC. In
future studies it will be important to test whether
neuromodulation is also efficacious in BoNT-A treated
patients, and whether the two treatments could be com-
bined in the treatment of patients with refractory detrusor
overactivity.
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